SARASOTA, Fla., Aug. 4, 2014 /PRNewswire/ -- Rock Creek
Pharmaceuticals, Inc., (NASDAQ: RCPI) announced that the Company
has been selected to present at the Next Generation Track at
BioPharm America 2014 in Boston
(Sept. 22-24, 2014) at The Boston
Marriott Copley Place.
Michael Mullan, MBBS, PhD,
Chairman and CEO of Rock Creek Pharmaceuticals, will present
preclinical and clinical data for anatabine citrate, a small
molecule cholinergic agonist which exhibits anti-inflammatory
pharmacological characteristics. Dr Mullan will outline the
company's regulatory strategy and ongoing drug development
initiatives advancing the lead molecule into phase I and phase II
studies.
About BioPharm America 2014
BioPharm America™ is where biotech industry partnerships get
started. Meet face-to-face with biotech and pharma executives from
around the world to identify and enter strategic relationships.
Equipped with partneringONE®, BioPharm America is the only event in
North America based on the same
reputable formula as EBD Group's acclaimed European events
BIO-Europe® and BIO-Europe Spring®.
Additional links and information:
Follow BioPharm America 2014 on Twitter: @EBDGroup
(hashtag: #BPA14).
About Anatabine Citrate:
Rock Creek Pharmaceuticals' Anatabine Citrate is a small
molecule, cholinergic agonist which exhibits anti-inflammatory
pharmacological characteristics. The Company has sponsored
extensive pre-clinical in vitro and in vivo studies resulting in
peer reviewed and published scientific journal articles, covering
inflammatory models of Multiple Sclerosis, Alzheimer's Disease, and
Auto-Immune Thyroiditis. In addition, the company's compilation of
human exposure, safety and tolerability data, provides important
insights for future clinical pathway progression.
About Rock Creek Pharmaceuticals, Inc.:
Rock Creek Pharmaceuticals, Inc. is an emerging drug development
company focused on the discovery, development and commercialization
of new drugs, formulations and compounds that provide therapies for
inflammatory conditions and behavioral health. Additionally,
through its subsidiary RCP Development, the Company is engaged in
the manufacturing and sale of nutraceutical dietary supplements
designed to promote maintenance of a healthy metabolism and
lifestyle.
For more information, visit: http://www.rockcreekpharma.com
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor
Relations
Rock Creek Pharmaceuticals
tjenkins@rockcreekpharma.com
203-216-2028
Certain statements contained in this release constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements identified by words such as
"believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The
statements in this release are based upon the current beliefs and
expectations of our company's management and are subject to
significant risks and uncertainties. Actual results may differ from
those set forth in the forward-looking statements. Numerous factors
could cause or contribute to such differences, including, but not
limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives,
including the continued development and market acceptance of our
nutraceutical dietary supplements products, the effect of any
competitive products, our ability to license and protect our
intellectual property, our ability to raise additional capital in
the future that is necessary to maintain our business, changes in
government policy and/or regulation, potential litigation by or
against us, any governmental review of our products or practices
and the outcome of the ongoing investigations as well as other
risks discussed from time to time in our filings with the
Securities and Exchange Commission, including, without limitation,
our annual report on Form 10-K for the fiscal year ended
December 31, 2013 filed on
March 17, 2014 and our latest 10-Q
Report filed on May 12, 2014. We
undertake no duty to update any forward-looking statement or any
information contained in this press release or in other public
disclosures at any time.
Logo -
http://photos.prnewswire.com/prnh/20140804/133073
SOURCE Rock Creek Pharmaceuticals, Inc.